Cellectis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectis SA ADR (CLLS)
Cellectis SA ADR stock price live, this page displays NASDAQ CLLS stock exchange data. View the CLLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectis SA ADR real time stock price chart below.
What Is the Cellectis SA ADR Stock Price Today?
The Cellectis SA ADR stock price today is 1,180.
What Is the Stock Symbol for Cellectis SA ADR?
The stock symbol for Cellectis SA ADR is "CLLS."
What Stock Exchange Does Cellectis SA ADR Trade On?
Cellectis SA ADR is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA ADR a Good Stock to Buy?
Determining whether Cellectis SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
What Is the Cellectis SA ADR Stock Price Today?
The Cellectis SA ADR stock price today is 1,180.
What Is the Stock Symbol for Cellectis SA ADR?
The stock symbol for Cellectis SA ADR is "CLLS."
What Stock Exchange Does Cellectis SA ADR Trade On?
Cellectis SA ADR is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA ADR a Good Stock to Buy?
Determining whether Cellectis SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.108
1.240
52 wk Range
0.881
5.450
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.1081.240
52 wk Range
0.8815.450
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
4.825
Upside
+308.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Cellectis receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Cellectis receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
2 Buy
2 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.825
(+308.90% Upside)
Cellectis SA ADR SWOT Analysis
Gene Therapy Pionee | Cellectis leads in allogeneic CAR T-cell therapies, with its proprietary TALEN® platform driving development of off-the-shelf cancer treatments |
Clinical Milestones | UCART22 advances to late-stage trials for B-cell leukemia, while UCART20x22 shows promise in non-Hodgkin lymphoma, showcasing pipeline strength |
Financial Stability | $198 million cash position funds operations into 2027, providing runway for clinical development and potential market entry |
Market Outlook | Analyst price targets range from $4 to $6, reflecting optimism in Cellectis' innovative approach and upcoming catalysts in the competitive CAR T-cell space |
Cellectis SA ADR Earnings Call Summary for Q3/2026
- Cellectis posted Q3 2026 loss of $0.61/share vs. forecast $0.19/share; revenue of $3.76M missed estimates of $15.19M by 75%.
- Company pivoting from legacy cell therapy to in vivo gene editing for dyslipidemias; exiting lasme-cel and eti-cel programs.
- Cash position fell to $149M from $211M year-end 2025; management projects runway into H2 2028 after 70% headcount reduction.
- Lead programs HEAL-101 (hypertriglyceridemia) and HEAL-201 (hypercholesterolemia) target clinical data in H2 2027 and H1 2028 respectively.
- Stock dropped 12.78% to $1.16 in premarket trading, nearing 52-week low amid restructuring costs and reduced collaboration revenue.
Last Updated: 2026/11/13, 15:50
Read Full TranscriptEarnings
Latest Release
Nov 13, 2026
EPS / Forecast
-0,61 / -0,19
Revenue / Forecast
3,76M / 15,19M
Compare CLLS to Peers and Sector
Metrics to compare | CLLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −1.6x | −0.2x | |
PEG Ratio | 0.15 | −0.04 | 0.00 | |
Price/Book | 2.1x | 1.2x | 2.6x | |
Price / LTM Sales | 1.3x | 3.1x | 2.8x | |
Upside (Analyst Target) | - | 568.9% | 63.4% | |
Fair Value Upside | Unlock | 10.3% | 9.5% | Unlock |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Cellectis ADR (CLLS) Stock Price Today?
The Cellectis ADR stock price today is 1,180 USD.
What Stock Exchange Does Cellectis ADR Trade On?
Cellectis ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cellectis ADR?
The stock symbol for Cellectis ADR is "CLLS."
What Is the Cellectis ADR Market Cap?
As of today, Cellectis ADR market cap is 83,430M USD.
What Is Cellectis ADR's Earnings Per Share (TTM)?
The Cellectis ADR EPS (TTM) is -0,65.
From a Technical Analysis Perspective, Is CLLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Cellectis ADR Stock Split?
Cellectis ADR has split 0 times.
How Many Employees Does Cellectis ADR Have?
Cellectis ADR has 227 employees.
What is the current trading status of Cellectis ADR (CLLS)?
As of Nov 13, 2026, Cellectis ADR (CLLS) is trading at a price of 1,180 USD, with a previous close of 1,330 USD. The stock has fluctuated within a day range of 1,108 USD to 1,240 USD, while its 52-week range spans from 0,881 USD to 5,450 USD.
What Is Cellectis ADR (CLLS) Price Target According to Analysts?
The average 12-month price target for Cellectis ADR is 4,825 USD, with a high estimate of 8 USD and a low estimate of 1.3 USD. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +308,90% Upside potential.
What Is the CLLS Premarket Price?
CLLS's last pre-market stock price is 1,120 USD. The pre-market share volume is 5 480,000, and the stock has decreased by -0,210, or -15,790%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.